ELV Stock Analysis: Elevance Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 90.381m USD | 12M Return: 22.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 679M
EPS Trend: -42.0%
Qual. Beats: 1
Rev. Trend: 97.1%
Qual. Beats: 8
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elevance Health is a major U.S. health benefits company that operates through four segments: Health Benefits, CarelonRx (pharmacy services), Carelon Services (healthcare-related services), and Corporate & Other. The company serves individual, employer group, Medicare, Medicaid, and federal employee members, offering a range of health plans alongside specialty products such as dental, vision, and stop loss insurance. It also runs home delivery and specialty pharmacies, ambulatory infusion centers, and a broad set of care management, behavioral health, palliative care, virtual care, and payment integrity services. Elevance markets under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, and is headquartered in Indianapolis.
As one of the largest U.S. managed care insurers, Elevance is an independent licensee of the Blue Cross Blue Shield Association, giving it access to the BlueCard network that allows members to receive covered care across all 50 states. Its Carelon branded services reflect a broader industry shift by large insurers toward vertical integration, combining insurance, pharmacy benefit management, and care delivery capabilities under a single corporate platform. The company was incorporated in 2001 and adopted the Elevance Health name in June 2022, having previously operated as Anthem, Inc.
- CMS Medicare Advantage rate cuts pressure premium margins
- CarelonRx and Carelon Services accelerate revenue diversification
- Medical cost trends and GLP-1 utilization pressure margins
| Net Income: 5.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.06 > 1.0 |
| NWC/Revenue: 10.84% < 20% (prev 1.51%; Δ 9.33% < -1%) |
| CFO/TA 0.06 > 3% & CFO 7.61b > Net Income 5.24b |
| Net Debt (-3.72b) to EBITDA (8.92b): -0.42 < 3 |
| Current Ratio: 1.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (220.4m) vs 12m ago -2.99% < -2% |
| Gross Margin: 23.16% > 18% (prev 27.74%; Δ -4.57% > 0.5%) |
| Asset Turnover: 163.2% > 50% (prev 153.0%; Δ 10.28% > 0%) |
| Interest Coverage Ratio: 5.39 > 6 (EBIT TTM 7.63b / Interest Expense TTM 1.42b) |
| A: 0.17 (Total Current Assets 67.0b - Total Current Liabilities 45.3b) / Total Assets 126b |
| B: 0.28 (Retained Earnings 35.8b / Total Assets 126b) |
| C: 0.06 (EBIT TTM 7.63b / Avg Total Assets 123b) |
| D: 0.54 (Book Value of Equity 43.9b / Total Liabilities 81.8b) |
| Altman-Z'' = 3.04 = A |
| DSRI: 1.33 (Receivables 22.8b/15.6b, Revenue 200b/183b) |
| GMI: 1.20 (GM 27.74% / 23.16%) |
| AQI: 0.56 (AQ_t 0.43 / AQ_t-1 0.77) |
| SGI: 1.09 (Revenue 200b / 183b) |
| TATA: -0.02 (NI 5.24b - CFO 7.61b) / TA 126b) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of July 05, 2026, the stock is trading at USD 417.89 with a total of 1,624,863 shares traded. Over the past week, the price has changed by +7.89%, over one month by +7.24%, over three months by +38.66% and over the past year by +22.66%.
Current recommended Stop Loss: 393.80 (which is 5.8% or 2.1 ATR below the current price).
Elevance Health has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy ELV.
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 418.7 | 0.2% |
P/E Trailing = 17.6426
P/E Forward = 14.4509
P/S = 0.419
P/B = 1.913
P/EG = 1.4158
Revenue TTM = 200b USD
EBIT TTM = 7.63b USD
EBITDA TTM = 8.92b USD
Long Term Debt = 30.8b USD (from longTermDebt, last quarter)
Short Term Debt = 724.0m USD (from shortTermDebt, last quarter)
Debt = 31.8b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.72b USD (calculated: Debt 31.8b - CCE 35.6b)
Enterprise Value = 86.7b USD (90.4b + Debt 31.8b - CCE 35.6b)
Interest Coverage Ratio = 5.39 (Ebit TTM 7.63b / Interest Expense TTM 1.42b)
EV/FCF = 13.44x (Enterprise Value 86.7b / FCF TTM 6.45b)
FCF Yield = 7.44% (FCF TTM 6.45b / Enterprise Value 86.7b)
FCF Margin = 3.22% (FCF TTM 6.45b / Revenue TTM 200b)
Net Margin = 2.62% (Net Income TTM 5.24b / Revenue TTM 200b)
Gross Margin = 23.16% ((Revenue TTM 200b - Cost of Revenue TTM 154b) / Revenue TTM)
Gross Margin QoQ = 18.14% (prev 23.48%)
Tobins Q-Ratio = 0.69 (Enterprise Value 86.7b / Total Assets 126b)
Interest Expense / Debt = 4.44% (Interest Expense 1.42b / Debt 31.8b)
Taxrate = 15.76% (980.0m / 6.22b)
NOPAT = 6.43b (EBIT 7.63b * (1 - 15.76%))
Current Ratio = 1.48 (Total Current Assets 67.0b / Total Current Liabilities 45.3b)
Debt / Equity = 0.73 (Debt 31.8b / totalStockholderEquity, last quarter 43.9b)
Debt / EBITDA = -0.42 (Net Debt -3.72b / EBITDA 8.92b)
Debt / FCF = -0.58 (Net Debt -3.72b / FCF TTM 6.45b)
Total Stockholder Equity = 43.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.27% (Net Income 5.24b / Total Assets 126b)
RoE = 11.95% (Net Income TTM 5.24b / Total Stockholder Equity 43.9b)
RoCE = 10.23% (EBIT 7.63b / Capital Employed (Equity 43.9b + L.T.Debt 30.8b))
RoIC = 9.03% (NOPAT 6.43b / Invested Capital 71.2b)
WACC = 5.59% (E(90.4b)/V(122b) * Re(6.24%) + D(31.8b)/V(122b) * Rd(4.44%) * (1-Tc(0.16)))
Discount Rate = 6.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.88 | Cagr: -2.96%
[DCF] Terminal Value 77.97% ; FCFF base≈5.34b ; Y1≈6.12b ; Y5≈9.01b
[DCF] Fair Price = 641.4 (EV 136b - Net Debt -3.72b = Equity 139b / Shares 217.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -42.02 | EPS CAGR: -2.44% | SUE: 2.66 | # QB: 1
Revenue Correlation: 97.10 | Revenue CAGR: 7.68% | SUE: 2.70 | # QB: 8
EPS current Quarter (2026-06-30): EPS=6.20 | Chg30d=-0.01% | Revisions=+0% | Analysts=20
EPS next Quarter (2026-09-30): EPS=5.09 | Chg30d=-0.21% | Revisions=-57% | Analysts=20
EPS current Year (2026-12-31): EPS=26.90 | Chg30d=-0.01% | Revisions=+79% | GrowthEPS=-11.2% | GrowthRev=-1.7%
EPS next Year (2027-12-31): EPS=29.25 | Chg30d=+0.00% | Revisions=+67% | GrowthEPS=+8.7% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +27% (up=48, down=27)